ArticleEClinicalMedicine2024

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.

Yangqing Zhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.